MRK SEC Filing News — Merck & Co., Inc.

Latest SEC filings for Merck & Co., Inc. (MRK) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme…
Sector: Healthcare Industry: Drug Manufacturers - General Market Cap: $348.1B CIK: 310158
20
Total Filings
0
Bullish Classifications
9
Bearish Classifications
10
Insider Transactions
0
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for MRK currently lean bearish. Of the 20 filing records displayed, 9 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
MRK Filing Activity Snapshot 2026-08-05 — 2026-10-01
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$10.72M
JENNIFER L ZACHARY · 2026-08-12
80,315 shares · Form 144
Form 144 Notices
9
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Merck & Co., Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 7 open-market sale and 3 compensation award. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×3
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Compensation award Tax / Compensation Filing 2026-10-01

MRK insider Form 4 filed for equity award, exercise, or tax withholding

Seidman Christine E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock 55 $145.31 $8.0K
Filing: Form 4 (Insider Transaction) Insider: Seidman Christine E (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-01

MRK insider Form 4 filed for equity award, exercise, or tax withholding

Karsanbhai Surendralal Lanca (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock 111 $145.31 $16.1K
Filing: Form 4 (Insider Transaction) Insider: Karsanbhai Surendralal Lanca (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-01

MRK insider Form 4 filed for equity award, exercise, or tax withholding

Coe Mary Ellen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock 206 $145.31 $29.9K
Filing: Form 4 (Insider Transaction) Insider: Coe Mary Ellen (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

MRK insider Guindo Chirfi (EVP, Access, Policy & Comms) sold 10,000 shares (~$1.35M)

Guindo Chirfi, listed as EVP, Access, Policy & Comms at Merck & Co., Inc., reported an open-market sale of 10,000 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,000 $135.00 $1.35M
Filing: Form 4 (Insider Transaction) Insider: Guindo Chirfi (EVP, Access, Policy & Comms) Shares: 10,000 Est. Value: $1.35M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

MRK insider Zachary Jennifer (EVP, General Counsel) sold 80,315 shares (~$10.72M)

Zachary Jennifer, listed as EVP, General Counsel at Merck & Co., Inc., reported an open-market sale of 80,315 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 41,494 $117.89 $4.89M
M Option exercise 13,433 $84.71 $1.14M
S Open-market sale 80,315 $133.46 $10.72M
M Option exercise derivative · Stock Option (Right to Buy) 41,494 — —
M Option exercise derivative · Stock Option (Right to Buy) 13,433 — —
Filing: Form 4 (Insider Transaction) Insider: Zachary Jennifer (EVP, General Counsel) Shares: 80,315 Est. Value: $10.72M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

MRK insider DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) sold 45,320 shares (~$5.94M)

DeLuca Richard R., listed as EVP&Pres, Merck Animal Heallth at Merck & Co., Inc., reported an open-market sale of 45,320 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 20,784 $130.43 $2.71M
S Open-market sale 7,410 $131.33 $973.2K
S Open-market sale 5,427 $132.35 $718.3K
S Open-market sale 11,099 $131.61 $1.46M
S Open-market sale 600 $132.04 $79.2K
Filing: Form 4 (Insider Transaction) Insider: DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) Shares: 45,320 Est. Value: $5.94M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-10

MRK insider DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) sold 6,050 shares (~$788.8K)

DeLuca Richard R., listed as EVP&Pres, Merck Animal Heallth at Merck & Co., Inc., reported an open-market sale of 6,050 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 805 $131.02 $105.5K
S Open-market sale 4,945 $130.23 $644.0K
S Open-market sale 300 $131.02 $39.3K
Filing: Form 4 (Insider Transaction) Insider: DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) Shares: 6,050 Est. Value: $788.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

MRK insider Maraldo David R. (EVP & Pres. MMD) sold 18,706 shares (~$2.41M)

Maraldo David R., listed as EVP & Pres. MMD at Merck & Co., Inc., reported an open-market sale of 18,706 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 6,311 $73.73 $465.3K
S Open-market sale 6,311 $128.72 $812.3K
M Option exercise 9,709 $87.10 $845.7K
S Open-market sale 9,709 $128.72 $1.25M
M Option exercise 2,686 $84.71 $227.5K
S Open-market sale 2,686 $128.72 $345.7K
M Option exercise derivative · Stock Option (Right to Buy) 6,311 — —
M Option exercise derivative · Stock Option (Right to Buy) 9,709 — —
M Option exercise derivative · Stock Option (Right to Buy) 2,686 — —
Filing: Form 4 (Insider Transaction) Insider: Maraldo David R. (EVP & Pres. MMD) Shares: 18,706 Est. Value: $2.41M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

MRK insider Williams David Michael (EVP,Chief Info&Digital Officer) sold 52,847 shares (~$6.81M)

Williams David Michael, listed as EVP,Chief Info&Digital Officer at Merck & Co., Inc., reported an open-market sale of 52,847 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 4,600 $77.62 $357.1K
S Open-market sale 4,600 $128.77 $592.3K
M Option exercise 13,542 $75.36 $1.02M
S Open-market sale 13,542 $128.77 $1.74M
M Option exercise 34,705 $73.73 $2.56M
S Open-market sale 34,705 $128.77 $4.47M
M Option exercise derivative · Stock Option (Right to Buy) 4,600 — —
M Option exercise derivative · Stock Option (Right to Buy) 13,542 — —
M Option exercise derivative · Stock Option (Right to Buy) 34,705 — —
Filing: Form 4 (Insider Transaction) Insider: Williams David Michael (EVP,Chief Info&Digital Officer) Shares: 52,847 Est. Value: $6.81M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

MRK insider Guindo Chirfi (EVP, Access, Policy & Comms) sold 15,000 shares (~$1.97M)

Guindo Chirfi, listed as EVP, Access, Policy & Comms at Merck & Co., Inc., reported an open-market sale of 15,000 MRK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 15,000 $131.00 $1.97M
Filing: Form 4 (Insider Transaction) Insider: Guindo Chirfi (EVP, Access, Policy & Comms) Shares: 15,000 Est. Value: $1.97M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 9 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Merck & Co., Inc. has 9 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-13

MRK Form 144 filed for proposed insider sale by CHIRFI GUINDO (10,000 shares) ~$1.35M

CHIRFI GUINDO filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHIRFI GUINDO Shares: 10,000 Est. Value: $1.35M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-12

MRK Form 144 filed for proposed insider sale by RICHARD ROBERT DELUCA JR (11,699 shares) ~$1.54M

RICHARD ROBERT DELUCA JR filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RICHARD ROBERT DELUCA JR Shares: 11,699 Est. Value: $1.54M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-12

MRK Form 144 filed for proposed insider sale by JENNIFER L ZACHARY (80,315 shares) ~$10.72M

JENNIFER L ZACHARY filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: JENNIFER L ZACHARY Shares: 80,315 Est. Value: $10.72M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

MRK Form 144 filed for proposed insider sale by RICHARD ROBERT DELUCA JR (12,837 shares) ~$1.69M

RICHARD ROBERT DELUCA JR filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RICHARD ROBERT DELUCA JR Shares: 12,837 Est. Value: $1.69M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-10

MRK Form 144 filed for proposed insider sale by RICHARD ROBERT DELUCA JR (20,784 shares) ~$2.71M

RICHARD ROBERT DELUCA JR filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RICHARD ROBERT DELUCA JR Shares: 20,784 Est. Value: $2.71M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-06

MRK Form 144 filed for proposed insider sale by CHIRFI GUINDO (15,000 shares) ~$1.97M

CHIRFI GUINDO filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHIRFI GUINDO Shares: 15,000 Est. Value: $1.97M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-06

MRK Form 144 filed for proposed insider sale by RICHARD ROBERT DELUCA JR (6,050 shares) ~$788.8K

RICHARD ROBERT DELUCA JR filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: RICHARD ROBERT DELUCA JR Shares: 6,050 Est. Value: $788.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-05

MRK Form 144 filed for proposed insider sale by DAVID M WILLIAMS (52,847 shares) ~$6.81M

DAVID M WILLIAMS filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: DAVID M WILLIAMS Shares: 52,847 Est. Value: $6.81M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-05

MRK Form 144 filed for proposed insider sale by DAVID MARALDO (18,706 shares) ~$2.41M

DAVID MARALDO filed a Form 144 with the SEC indicating intent to sell MRK (Merck & Co., Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: DAVID MARALDO Shares: 18,706 Est. Value: $2.41M
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Merck & Co., Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-07

MRK filed Quarterly Report (10-Q)

Merck & Co., Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Merck & Co., Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MRK. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MRK SEC Filings

What SEC filings does Merck & Co., Inc. submit to the SEC?

Merck & Co., Inc. (MRK) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about MRK?

A Form 4 for MRK discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Merck & Co., Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for MRK?

The 10-K is Merck & Co., Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all MRK SEC filings directly on EDGAR?

You can view all historical Merck & Co., Inc. filings on the SEC EDGAR company page for MRK. Each filing card on this page links directly to the original SEC document.

How often does Merck & Co., Inc. file with the SEC?

Merck & Co., Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling MRK shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for MRK

MRK Full Stock Analysis MRK Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MRK analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MRK stock analysis page.

MRK Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer